Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


AstraZeneca Breast Cancer Study Locator Service 1-877-400-4655
az-bcsl@careboxhealth.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Back

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Recruiting

Open to: ALL

Age: 18.0 - 130.0

Cambridge Manchester Sutton Oxford

Medical Conditions

Lung Neoplasms
Prostatic Neoplasms
Pancreatic Neoplasms
Ovarian Neoplasms
Small Cell Lung Carcinoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2020 Mar 2027

Publications

"Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkila J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301."; "35929986"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Oral PARP inhibitor

Intervention Arm Group : Module 1: AZD5305 Monotherapy;Module 2: AZD5305 + Paclitaxel;Module 3: AZD5305 + Carboplatin with or without Paclitaxel;Module 4: AZD5305 + Trastuzumab Deruxtecan;Module 5 AZD5305 + Datopotamab Deruxtecan;Module 6 AZD5305 + Camizestrant;

Intervention Type : DRUG
Intervention Description : IV Anti-microtubule agent

Intervention Arm Group : Module 2: AZD5305 + Paclitaxel;Module 3: AZD5305 + Carboplatin with or without Paclitaxel;

Intervention Type : DRUG
Intervention Description : IV Platinum chemotherapeutic

Intervention Arm Group : Module 3: AZD5305 + Carboplatin with or without Paclitaxel;

Intervention Type : DRUG
Intervention Description : IV Antibody-drug conjugate

Intervention Arm Group : Module 4: AZD5305 + Trastuzumab Deruxtecan;

Intervention Type : DRUG
Intervention Description : IV Antibody-drug conjugate

Intervention Arm Group : Module 5 AZD5305 + Datopotamab Deruxtecan;

Intervention Type : DRUG
Intervention Description : Oral SERD Molecule

Intervention Arm Group : Module 6 AZD5305 + Camizestrant;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Sutton
    SM2 5PT
  • Research Site
    Oxford
    OX3 7LE

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


AstraZeneca Breast Cancer Study Locator Service 1-877-400-4655
az-bcsl@careboxhealth.com



The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04644068
Last updated 18 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top